NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFERING OF THE SECURITIES DESCRIBED HEREIN
TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) — REVIVE THERAPEUTICS LTD. RVVRVVTF (“Revive” or the “Company“) announces that it has completed the second and final tranche of its previously announced private placement (see press releases dated January 24, 2024 and January 31, 2024) (the “Offering“) through the issuance of 33,917,428 units (each, a “Unit“), at a price of $0.035 per Unit, for gross proceeds of $1,187,110. The total amount raised from the first and second closing of the Offering is $2,100,610.
Each Unit was composed of one common share (“common action“) in the capital of the Company and half (1/2) of a purchase guarantee of Common Shares (“Order“) of the Company. Each full Warrant entitles its holder to acquire one additional Common Share at a price of $0.05 per Common Share for a period of thirty-six (36) months from the closing date (the “Closure Date“) of the Offer.
The Company intends to use the net proceeds from the Offering for clinical work on long COVID and other potential indications, advancement of government studies, potential repayment of certain arm's length accounts payable and general working capital purposes.
In connection with the Offering, the Company paid finder's fees and issued finder's warrants to Hampton Securities Limited, PI Financial Corp. and EMD Financial Inc. consisting of an aggregate of $8,764.00 in cash and 250,400 warrants entitling holders to purchase up to a total of 250,400 Company Units (the “Compensation Units“), at a price of $0.05 per Remuneration Unit, for a period of eighteen (18) months following the Closing Date.
All securities issued pursuant to the second and final closing of the Offering are subject to a statutory hold period of four months and one day expiring on June 24, 2024.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapies for infectious diseases and rare disorders, and is prioritizing drug development efforts to take advantage of various regulatory incentives granted by the FDA, such as Emergency Use Authorization , Orphan Drug, Fast Tracking and Breakthrough Therapy Designations. The Company is currently exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of psilocybin-based therapies through several programs. For more information visit www.ReviveThera.com.
On behalf of the Board of Directors,
“Michael Frank, CEO”
For more information contact:
michael frank
Executive Director
Revive Therapeutics Ltd.
Telephone: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Cautionary and Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “project”, “estimate” and similar expressions and statements relating to matters that are not historical . Facts are intended to identify forward-looking information and are based on Revive's current beliefs or assumptions as to the outcome and timing of such future events. Forward-looking information contained in this press release includes information with respect to the Offering and the Company's cannabinoid, psychedelics and infectious disease programs. Forward-looking information is based on reasonable assumptions that Revive has made as of the date of the information and is subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as requires applicable securities laws. The above statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three months ended September 30, 2023 (“MD&A“), dated November 29, 2023, which is available on the Company's profile at www.sedarplus.ca.
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States from America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Law of 1933“) or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the issuer and its management, as well as financial statements.
